Table 1:

Study population baseline characteristics.

Subject	Age	Gender	Duration	IgE	Dosing	BslUAS7	MidPtDay	BasoPheno	BasoCount
1	62	F	5	191	0.019	24.5	20	NR	B
2	34	F	<1	347	0.013	16.5	10	R	NB
3	50	F	4	133	0.024	23.5	20	NR	B
4	32	F	<1	21.4	0.238	32	6	R	NB
5	62	F	4	78.6	0.027	22	10	R	NB
6	39	F	<1	5.3	0.821	32	10	NR	B
7	31	M	2	610	0.004	20.5	6	R	NB
8	33	F	16	1558	0.002	25.5	20	R	B
9	39	M	1	< 2	2.054	42	30*	NR	B
10	52	M	50	153	0.020	30.5	30*	Unclassified	B
11	35	M	<1	< 2	1.586	35.5	20	NR	B
12	54	M	1	13.5	0.289	36	30*	NR	B
13	67	F	10	70.8	0.059	29	6	NR	NB
14	36	F	20	146	0.025	21.5	6	R	NB
15	71	F	2	149	0.037	41.5	30	NR	NB
16	29	M	8	4.2	0.854	32	30*	NR	B
17	36	F	1	197	0.016	34	6	NR	NB
18	22	F	6	56.3	0.084	23.5	30	R	NB
Average	44	67% F	7.4	207	0.340	29	17.7
R/NB	36	83% F	5.6	210	0.065	23^	11.3
NR/NB	58	100% F	4.3	139	0.037	35	14.0
NR/B	44	43% F	2.9	50	0.807	32	22.9

^*Indicates subjects that did not reach 50% UAS-7 reduction by day 30.

^{^}ANOVA p=0.0473

Duration = years of disease

Dosing = calculated dose of omalizumab in mg, per Kg body weight per IU IgE

BslUAS-7 = baseline UAS-7 score

MidPtDay = day at which symptom drop was greater than 50%

BasoPheno = anti-IgE functional category for the subject (NR = non-responder, R = responder)

BasoCount = Basophil count (B = basopenic, NB = non-basopenic)